Advances in Minimally Invasive Treatment Options for Benign Prostatic Hyperplasia

Dean Elterman, MD, discusses historical treatment options for BPH, including both pharmacotherapy and surgical methods, their effectiveness, and how to identify patients who would benefit from treatment based on quality of life, risk of lower urinary tract symptoms, and other factors. It also addresses challenges such as long-term complications and patient adherence.

Dean Elterman, MD, covers minimally invasive surgical therapies (MIST) for BPH, including laser therapy, prostatic urethral lift, and others, their impact on BPH management, AUA guidelines, patient selection, and the role of patient preference in choosing between MIST, medication, and surgery.

Dean Elterman, MD, compares minimally invasive surgical therapy (MIST) options for prostate treatment, discussing factors influencing choice, patient experience differences, and clinical and nonclinical factors such as prostate size, symptom severity, and patient preferences.

Dean Elterman, MD, discusses real-world outcomes of minimally invasive surgical therapies for benign prostate dysplasia, including improvements in quality of life, symptom relief, comparisons with clinical study results, and general patient feedback, while also sharing tips for building rapport and educating patients on their treatment options.

Dean Elterman, MD, discusses how a comprehensive approach to diagnosing and managing benign prostatic hyperplasia (BPH) involves a combination of symptom assessment, lifestyle modifications, pharmacotherapy, and regular follow-up to optimize patient outcomes.

Dean Elterman, MD, discusses how minimally invasive surgical therapies (MIST) are increasingly integrated into the treatment landscape for benign prostatic hyperplasia (BPH), addressing unmet needs and offering new options, while also highlighting ongoing trials and investigations that aim to further refine these approaches.